MD Anderson and Innovent Biologics Announce a Strategic Collaboration to Develop Anti-PD-1 Thera#py TYVYT in Rare Cancers
May 19, 2020
May 19, 2020
HOUSTON, Texas, May 19 -- The University of Texas's MD Anderson Cancer Center issued the following news release:
The University of Texas MD Anderson Cancer Center and Innovent Biologics, Inc. announced a strategic collaboration agreement to co-develop TYVYT(R) (sintilimab injection), Innovent's anti-PD-1 monoclonal antibody, in rare cancers in the U. S.
The joint development will focus on advancing sintilimab as an effective immune checkpoint inhibitor for patients with . . .
The University of Texas MD Anderson Cancer Center and Innovent Biologics, Inc. announced a strategic collaboration agreement to co-develop TYVYT(R) (sintilimab injection), Innovent's anti-PD-1 monoclonal antibody, in rare cancers in the U. S.
The joint development will focus on advancing sintilimab as an effective immune checkpoint inhibitor for patients with . . .